Brivaracetam not checked
UCB Biopharma SRL · UCB34714
FollowEvery change as it happens, and a Monday email
Trials
3 active
21 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.”In the company’s words, NCT06315322 on ClinicalTrials.gov
- Main trialPhase 3
- “The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.”In the company’s words, NCT06315322 on ClinicalTrials.gov
- Other names
- BRV · Briviact · UCB34714
Other drugs for Childhood Absence Epilepsy
- BMB-101Bright Minds Biosciences · Phase 2
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- BrivekaZodiac Produtos Farmaceuticos S.A. · NCT07800533 · finished
Coming up2
- 16 Nov 2029Phase 3 trial completes · ClinicalTrials.gov
- 8 Jul 2030Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT04715646
Trials21
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 16 Nov 2029 | A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | |
| Phase 3Active, not recruiting | 8 Jul 2030 | A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures | |
| Phase 3Completed | Jan 2008 | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults | |
| Phase 3Completed | Dec 2008 | Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures | |
| Phase 3Completed | Feb 2009 | Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures | |
| Phase 3Completed | May 2014 | Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures | |
| Phase 3Completed | Sep 2017 | This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment | |
| Phase 3Completed | 18 Apr 2019 | Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy | |
| Phase 3Completed | May 2019 | Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy | |
| Phase 3Terminated | 3 Sep 2020 | A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures | |
| Phase 3Completed | 27 Mar 2021 | A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization | |
| Phase 3Completed | 3 Feb 2022 | Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy | |
| Phase 3Completed | 30 Jun 2022 | A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy | |
| Phase 3Completed | 24 Dec 2024 | A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization | |
| Phase 3Completed | 18 Mar 2025 | A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | |
| Phase 3Completed | 7 Jul 2026 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | |
| Phase 2Completed | 4 Nov 2020 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy | |
| Phase 1Completed | 8 Jun 2021 | A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects | |
| Phase 1Completed | 13 May 2022 | A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants | |
| Phase 1Completed | 4 Jun 2024 | A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants | |
| Phase 3Authorised | not given | FAST ACUTE SEDATION AT INTENSIVE CARE VS. HIGH-DOSE I.V. ANTI-SEIZURE MEDICATION FOR TREATMENT OF NON-CONVULSIVE STATUS EPILEPTICUS - A RANDOMIZED, MULTICENTER TRIAL (FAST TRIAL) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026